MEDICA 2016: GATC Biotech Showcases World’s Only Service Lines for Direct Comparison of Liquid and Tissue Biopsy Samples

GATC Biotech, a world-wide leading provider of innovative sequencing and diagnostic solutions, is pleased to present the company’s exclusive product portfolio for simultaneous analysis of tumor tissue and liquid biopsy samples at this year’s MEDICA. With GATCLIQUID, the world’s leading service line for liquid biopsy analysis, GATC Biotech offers the sole opportunity for exome, cancer panel or single gene sequencing from cell-free DNA (cfDNA). The same services are perfectly complemented by INVIEW sequencing solutions for genomic analysis of tumor tissue. Together or alone, the products offer mutation profiling of individual cancers for improved personalized monitoring of disease progression.

“The great thing about our cancer research portfolio is that we offer scientists the opportunity to compare liquid biopsy samples with matched tissue biopsies,” said Dr. Paprotka, Director Research & Development at GATC Biotech. “This compatibility makes comparative analysis of mutations detected in either liquid or tissue biopsies easily possible.”

The three highly-sensitive assays differ in the scope of mutational analysis. GATCLIQUID ONCOEXOME provides an overview of all somatic mutations in the protein coding regions of the tumor. INVIEW HUMANEXOME is this product’s complement for tissue biopsy analysis. GATCLIQUID ONCOPANEL and INVIEW ONCOPANEL target more than 200 actionable mutations from 50 carefully selected cancer drivers in blood or tumor tissue respectively. GATCLIQUID ONCOTARGET provides highly sensitive detection of a single tumor mutation that is the most informative in a specific cancer case.

“Data from concordance studies comparing liquid biopsies with standard tissue testing is urgently needed to help establish liquid biopsies in a clinical setting,” continued Dr. Paprotka. “Taking this into account, our expansive cancer research portfolio makes GATC Biotech the perfect partner for all clinical studies in the field of oncology diagnostics.”